AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7400
-0.0200 (-2.63%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.7600
Open0.7406
Bid0.7405 x 1400
Ask0.7900 x 900
Day's Range0.7400 - 0.7900
52 Week Range0.4160 - 3.1000
Volume98,346
Avg. Volume338,832
Market Cap19M
Beta (3Y Monthly)2.13
PE Ratio (TTM)N/A
EPS (TTM)-0.8920
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.80
  • AZRX: 3Q:19 Review
    Zacks Small Cap Research

    AZRX: 3Q:19 Review

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 third quarter 10-Q with the SEC for the three month period ending September 30, 2019. Highlights for the reporting period and to date include the announcement and first dosing in a new combination trial for patients with severe EPI, the readout from the OPTION trial, the

  • GlobeNewswire

    AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    Under the purchase agreement, AzurRx will have the right to sell up to $15 million of its stock to Lincoln Park over a 30-month period, upon satisfaction of the conditions in the purchase agreement, including after a registration statement registering the resale of shares to be sold to Lincoln Park under the purchase agreement is declared effective by the Securities and Exchange Commission (SEC). AzurRx, from time to time over a 30 month period, will have the right, at its sole discretion, to sell up to $15 million of its stock to Lincoln Park.

  • GlobeNewswire

    AzurRx BioPharma CEO Issues Letter to Shareholders

    AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the following letter to its shareholders and the investment community from its newly appointed CEO, James Sapirstein. It is with great pleasure that I am writing to you as the new President and Chief Executive Officer of AzurRx BioPharma, Inc. By way of background, I have over 35 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • GlobeNewswire

    AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Cystic Fibrosis Foundation (CFF) Data Safety Monitoring Board (DSMB) has completed  its review of the Company’s final results of the Phase 2 OPTION trial and has found no safety concerns for MS1819-SD. Additionally, the group supports the Company’s plan to proceed to a higher 4-gram dose of MS1819-SD in its next planned Phase 2 clinical trial.

  • GlobeNewswire

    AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has dosed the first patients in its Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) who suffer from severe exocrine pancreatic insufficiency (EPI).

  • GlobeNewswire

    AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that James Sapirstein has been appointed to serve as the Company’s President and Chief Executive Officer following the resignation of Thijs Spoor from the same positions. Mr. Sapirstein, who most recently served as chief executive officer and board member for ContraVir Pharmaceuticals, Inc. (now known as Hepion Pharmaceuticals, Inc. (NASADQ:HEPA)), has nearly 36 years of pharmaceutical industry experience spanning areas such as drug development and commercialization.

  • AZRX: OPTION Trial Readout
    Zacks Small Cap Research

    AZRX: OPTION Trial Readout

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) announced Phase II OPTION trial results for MS1819 in cystic fibrosis (CF) patients. Data provided was sparse, but the summary highlighted the positive safety profile for MS1819 and the utility of the drug in comparison with porcine enzyme replacement

  • Benzinga

    AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency

    AzurRx is working on developing non-systemic, recombinant therapies for gastrointestinal diseases. The company said the results of the Phase 2 OPTION trial that is evaluating its MS1819 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis showed that the primary efficacy endpoint of coefficient of fat absorption, or CFA, was comparable to that in a previous Phase 2 study in patients with chronic pancreatitis. Despite the study not being powered for statistical significance, the data showed meaningful efficacy results, with about 50% of patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies, or PERT, AzurRx said.

  • GlobeNewswire

    AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

    Results showed that the primary efficacy endpoint of coefficient of fat absorption (CFA) was comparable to the CFA in a prior phase 2 study in patients with chronic pancreatitis, while using the same dose of MS1819.  The dose used in both studies was 2 gram/day, which was selected in agreement with FDA as a bridging dose. Although the study was not powered for statistical significance, the data also demonstrated meaningful efficacy results, with approximately 50% of the patients showing CFAs high enough to reach non-inferiority with porcine enzyme replacement therapies (PERT).

  • What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?

    A look at the shareholders of AzurRx BioPharma, Inc. (NASDAQ:AZRX) can tell us which group is most powerful. Large...

  • Zacks Small Cap Research

    AZRX: OPTION & Combo Trial Underway

    By John Vandermosten, CFA NASDAQ:AZRX READ THE FULL AZRX RESEARCH REPORT AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its 2019 second quarter 10-Q with the SEC for the three month period ending June 30, ...

  • GlobeNewswire

    AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, reported financial results for the three and six months ended June 30, 2019 and highlighted recent corporate progress. Announced that the first patients were dosed in an open-label, cross-over Phase II OPTION Study with MS1819-SD for exocrine pancreatic insufficiency (“EPI”) in cystic fibrosis (“CF”) in February 2019 and that the study enrollment target was met in May 2019. The Company continues to expect results from the study in September 2019.

  • ACCESSWIRE

    AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. The Company also granted the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock, at the public offering price, less underwriting discounts and commissions.

  • ACCESSWIRE

    AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

    BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. AzurRx expects to receive aggregate gross proceeds of $5.0 million from the offering. The offering is expected to close on or about July 22, 2019, subject to customary closing conditions.

  • GlobeNewswire

    AzurRx BioPharma Announces Proposed Public Offering of Common Stock

    H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.  National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager for the offering.

  • Zacks Small Cap Research

    AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI

    The effort will examine combination use of MS1819-SD and pancreatic enzyme replacement therapy (PERT) for cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). This is a subset of CF patients that are suffer from malnutrition and fail to absorb sufficient fat despite taking the maximum dose of PERT therapy. The new study will be conducted at six sites in Hungary with an enrollment target of 28.

  • GlobeNewswire

    AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

    NEW YORK, July 08, 2019 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies.

  • GlobeNewswire

    AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

    Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency.

  • GlobeNewswire

    AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers

    The inhibitors are a novel, potent and selective group of anti-microbials that have the potential to safely eradicate Helicobacter pylori (H. pylori) bacterial infections that would spare the normal microbiome and would not precipitate antibiotic resistance in off-target bacterial species.

  • How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • Zacks Small Cap Research

    AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients

    On May 20th AzurRx BioPharma, Inc. (AZRX) presented secondary endpoint results for its Phase II Chronic Pancreatitis (CP) study, which completed clinical work in June 2018. The update follows topline and primary endpoint results released from the same trial last fall, which found a coefficient of fat absorption of 21.8% statistically significant to a p value of 0.002. The MS1819-SD Phase 2a open-label, dose escalation study was conducted in France, Australia and New Zealand.

  • GlobeNewswire

    AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has reached its enrollment target of 30-35 patients in its ongoing Phase II OPTION study of MS1819-SD for exocrine pancreatic insufficiency in patients with cystic fibrosis (CF).  The Company has completed screening activities for enrollment of the study, which is taking place across investigative sites in North America and Poland.

  • GlobeNewswire

    AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today released new data for its lead development candidate MS1819-SD at the 2019 Digestive Disease Week (DDW) Conference. The presentation entitled “Results from a Phase II Study of MS1819, a Recombinant Lipase for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Chronic Pancreatitis” was delivered by Dr. Nam Q. Nguyen, et al., on May 20, 2019.

  • GlobeNewswire

    AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial

    AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has now surpassed the 50% enrollment target in its ongoing Phase II OPTION study of MS1819-SD for exocrine pancreatic insufficiency in patients with cystic fibrosis (CF). The Phase II multi-center OPTION study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine pancreatic enzyme replacement therapy (PERT) standard of care for exocrine pancreatic insufficiency in CF patients.  Planned enrollment is expected to include approximately 30 CF patients, with top-line results expected in Summer 2019.

  • Zacks Small Cap Research

    AZRX: CF Study Up and Enrolling; Target to $8

    Highlights for the year and to date include participation in investment conferences, the addition of Dr. James Pennington as CMO, presentation of favorable trial data from chronic pancreatitis patients, the launch of the cystic fibrosis trial, and acquisition of rights from Protea and Mayoly. Research and development expenses were up 108% compared to the prior year period.